Oxaliplatin-Loaded Mil-100(Fe) for Chemotherapy-Ferroptosis Combined Therapy for Gastric Cancer

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2024 Apr 15

PMID 38617668

Authors

Boyao Sun

Xuewei Zheng

Xiaoyu Zhang

Huaiyu Zhang

Yang Jiang

Affiliations

Soon will be listed here.

Abstract

Oxaliplatin (Oxa) is a commonly used chemotherapy drug in the treatment of gastric cancer, but its toxic side effects and drug resistance after long-term use have seriously limited its efficacy. Loading chemotherapy drugs with nanomaterials and delivering them to the tumor site are common ways to overcome the above problems. However, nanomaterials as carriers do not have therapeutic functions on their own, and the effect of single chemotherapy is relatively limited, so there is still room for progress in related research. Herein, we construct Oxa@Mil-100(Fe) nanocomposites by loading Oxa with a metal-organic framework (MOF) Mil-100(Fe) with high biocompatibility and a large specific surface area. The pore structure of Mil-100(Fe) is conducive to a large amount of Oxa loading with a drug-loading rate of up to 27.2%. Oxa@Mil-100(Fe) is responsive to the tumor microenvironment (TME) and can release Oxa and Fe under external stimulation. On the one hand, Oxa can inhibit the synthesis of DNA and induce the apoptosis of gastric cancer cells. On the other hand, Fe can clear overexpressed glutathione (GSH) in TME and be reduced to Fe, inhibiting the activity of glutathione peroxidase 4 (GPX4), leading to the accumulation of intracellular lipid peroxides (LPO), and at the same time releasing a large number of reactive oxygen species (ROS) through the Fenton reaction, inducing ferroptosis in gastric cancer cells. With the combination of apoptosis and ferroptosis, Oxa@Mil-100(Fe) shows a good therapeutic effect, and the killing effect on gastric cancer cells is obvious. In a nude mouse model of subcutaneous tumor transplantation, Oxa@Mil-100(Fe) shows a significant inhibitory effect on tumor growth, with an inhibition rate of nearly 60%. In addition to its excellent antitumor activity, Oxa@Mil-100(Fe) has no obvious toxic or side effects. This study provides a new idea and method for the combined treatment of gastric cancer.

Citing Articles

Design of pH-Responsive Nanomaterials Based on the Tumor Microenvironment.

Liu Y, Si L, Jiang Y, Jiang S, Zhang X, Li S Int J Nanomedicine. 2025; 20():705-721.

PMID: 39845771 PMC: 11752822. DOI: 10.2147/IJN.S504629.

Ferroptosis in Cancer Therapy: Mechanisms, Small Molecule Inducers, and Novel Approaches.

Luo Y, Bai X, Zhang L, Hu Q, Zhang N, Cheng J Drug Des Devel Ther. 2024; 18:2485-2529.

PMID: 38919962 PMC: 11198730. DOI: 10.2147/DDDT.S472178.

References

Li Y, Liu J, Wu S, Xiao J, Zhang Z . Ferroptosis: opening up potential targets for gastric cancer treatment. Mol Cell Biochem. 2023; 479(11):2863-2874. DOI: 10.1007/s11010-023-04886-x. View

Sun Y, Zheng L, Yang Y, Qian X, Fu T, Li X . Metal-Organic Framework Nanocarriers for Drug Delivery in Biomedical Applications. Nanomicro Lett. 2021; 12(1):103. PMC: 7770922. DOI: 10.1007/s40820-020-00423-3. View

Ajani J, DAmico T, Bentrem D, Chao J, Cooke D, Corvera C . Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(2):167-192. DOI: 10.6004/jnccn.2022.0008. View

Zhang M, Jin H, Liu Y, Wan L, Liu S, Zhang H . L-Arginine self-delivery supramolecular nanodrug for NO gas therapy. Acta Biomater. 2023; 169:517-529. DOI: 10.1016/j.actbio.2023.07.055. View

Claes B, Boudewijns T, Muchez L, Hooyberghs G, Van der Eycken E, Vanderleyden J . Smart Metal-Organic Framework Coatings: Triggered Antibiofilm Compound Release. ACS Appl Mater Interfaces. 2017; 9(5):4440-4449. DOI: 10.1021/acsami.6b14152. View

Shashikumar U, Joshi S, Srivastava A, Tsai P, Shree K, Suresh M . Trajectory in biological metal-organic frameworks: Biosensing and sustainable strategies-perspectives and challenges. Int J Biol Macromol. 2023; 253(Pt 6):127120. DOI: 10.1016/j.ijbiomac.2023.127120. View

Stockwell B, Friedmann Angeli J, Bayir H, Bush A, Conrad M, Dixon S . Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017; 171(2):273-285. PMC: 5685180. DOI: 10.1016/j.cell.2017.09.021. View

Yang K, Luo H, Zeng M, Jiang Y, Li J, Fu X . Intracellular pH-Triggered, Targeted Drug Delivery to Cancer Cells by Multifunctional Envelope-Type Mesoporous Silica Nanocontainers. ACS Appl Mater Interfaces. 2015; 7(31):17399-407. DOI: 10.1021/acsami.5b04684. View

Rasheed T, Rizwan K, Bilal M, Iqbal H . Metal-Organic Framework-Based Engineered Materials-Fundamentals and Applications. Molecules. 2020; 25(7). PMC: 7180910. DOI: 10.3390/molecules25071598. View

10.

Low L, Wu J, Lee J, Tey B, Goh B, Gao J . Tumor-responsive dynamic nanoassemblies for targeted imaging, therapy and microenvironment manipulation. J Control Release. 2020; 324:69-103. DOI: 10.1016/j.jconrel.2020.05.014. View

11.

Rezaei M, Abbasi A, Varshochian R, Dinarvand R, Jeddi-Tehrani M . NanoMIL-100(Fe) containing docetaxel for breast cancer therapy. Artif Cells Nanomed Biotechnol. 2017; 46(7):1390-1401. DOI: 10.1080/21691401.2017.1369425. View

12.

Cai W, Chu C, Liu G, Wang Y . Metal-Organic Framework-Based Nanomedicine Platforms for Drug Delivery and Molecular Imaging. Small. 2015; 11(37):4806-22. DOI: 10.1002/smll.201500802. View

13.

Di Nunzio M, Agostoni V, Cohen B, Gref R, Douhal A . A "ship in a bottle" strategy to load a hydrophilic anticancer drug in porous metal organic framework nanoparticles: efficient encapsulation, matrix stabilization, and photodelivery. J Med Chem. 2013; 57(2):411-20. DOI: 10.1021/jm4017202. View

14.

Hong T, Shen X, Syeda M, Zhang Y, Sheng H, Zhou Y . Recent advances of bioresponsive polymeric nanomedicine for cancer therapy. Nano Res. 2022; 16(2):2660-2671. PMC: 9664041. DOI: 10.1007/s12274-022-5002-2. View

15.

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

16.

Liu J, Zhang L, Lei J, Shen H, Ju H . Multifunctional Metal-Organic Framework Nanoprobe for Cathepsin B-Activated Cancer Cell Imaging and Chemo-Photodynamic Therapy. ACS Appl Mater Interfaces. 2016; 9(3):2150-2158. DOI: 10.1021/acsami.6b14446. View

17.

Shu F, Lv D, Song X, Huang B, Wang C, Yu Y . Fabrication of a hyaluronic acid conjugated metal organic framework for targeted drug delivery and magnetic resonance imaging. RSC Adv. 2022; 8(12):6581-6589. PMC: 9078328. DOI: 10.1039/c7ra12969f. View

18.

Chen J, Wang Y, Niu H, Wang Y, Wu A, Shu C . Metal-Organic Framework-Based Nanoagents for Effective Tumor Therapy by Dual Dynamics-Amplified Oxidative Stress. ACS Appl Mater Interfaces. 2021; 13(38):45201-45213. DOI: 10.1021/acsami.1c11032. View

19.

Sun Y, Xie Y, Tang H, Ren Z, Luan X, Zhang Y . In vitro and in vivo Evaluation of a Novel Estrogen-Targeted PEGylated Oxaliplatin Liposome for Gastric Cancer. Int J Nanomedicine. 2022; 16:8279-8303. PMC: 8712509. DOI: 10.2147/IJN.S340180. View

20.

Zedan A, Hansen T, Fex Svenningsen A, Vilholm O . Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers. Clin Colorectal Cancer. 2013; 13(2):73-80. DOI: 10.1016/j.clcc.2013.11.004. View